Isomorphic Labs raises $5 billion to push AI-designed drugs toward human trials
Isomorphic Labs has closed a $5 billion Series C co-led by Greenoaks and Sequoia Capital, just six months after its $2.1 billion Series B. The money funds its IsoDDE drug-design engine and the push to take its first AI-designed medicines into human trials — the test the whole field has been waiting for.
- $5 billion Series C, announced November 17, 2026, co-led by Greenoaks and Sequoia Capital. The round was oversubscribed; Andreessen Horowitz joined as a new investor, Alphabet invested again, and every existing backer — Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund — took part.
- It is the company’s third external round in under two years: $600 million in March 2025, $2.1 billion in May 2026, and now $5 billion — more than $7 billion raised in 2026 alone.
- The cash funds IsoDDE, Isomorphic’s drug-design engine, which unifies simulation models across therapeutic areas and drug types to design candidate molecules. The company reports positive preclinical results in oncology and immunology programs, both internal and with partners.
- No valuation was disclosed. In October, Bloomberg reported Isomorphic was in talks to raise at a valuation of at least $40 billion, potentially $50 billion.
- Founded in 2021 as a spinout of Google DeepMind, Isomorphic is led by CEO Demis Hassabis and President Max Jaderberg, from headquarters in London with offices in Cambridge, Massachusetts and Lausanne, Switzerland.

The round closed fast. Isomorphic announced the $5 billion Series C on Tuesday, November 17, describing it as oversubscribed, with Greenoaks and Sequoia Capital sharing the lead. Andreessen Horowitz joined as a new investor, Alphabet put in more money, and every existing backer returned — Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. The company did not disclose a valuation.
Six months, $7 billion#
The pace is the story as much as the size. Isomorphic raised $2.1 billion in May 2026 in a Series B led by Thrive Capital, and $600 million in March 2025, also led by Thrive. The new round brings its external fundraising to $7.7 billion in under two years — $7.1 billion of it in 2026 alone. For a company with no drug in human trials yet, that is an extraordinary vote of confidence, and it makes Isomorphic one of the best-capitalized private AI companies in the world.
It also fits Alphabet’s playbook for its big bets. Waymo raised $16 billion at a $126 billion valuation earlier this year, and Isomorphic is now the second Alphabet-linked company to command a pharma- or auto-scale war chest on the strength of AI models rather than products on the market. The October funding talks — which reportedly priced Isomorphic at $40 billion or more — clearly found their audience: this round’s investor list reads like a roll call of the firms that have decided AI-designed medicine is a matter of when, not if.
What IsoDDE actually does#
IsoDDE is Isomorphic’s proprietary drug-design engine: a suite of simulation models that work across therapeutic areas and drug types, exploring vast chemical spaces to design molecules with the properties a drug needs. Paired with agents that reason over complex biological systems, the models are meant to turn drug discovery from a slow, failure-prone search into something closer to engineering — design the molecule on a computer, then test it in the lab.
The engine descends from DeepMind’s AlphaFold, the Nobel-winning system for predicting protein structures, and Isomorphic says the simulation models inside IsoDDE now push predictions toward experimental accuracy. The company reports positive preclinical results from internal programs in oncology and immunology, and from partnered programs — results it says put it in position to enter the clinic. Those results are company-reported, not independently verified, and preclinical success is a long way from a medicine.
The money goes to trials, not just models#
What the $5 billion buys, according to the announcement, is the next stage of the pipeline rather than more of the same. The company will keep maturing IsoDDE and push into new areas of biology, build a partner ecosystem around understanding disease mechanisms, and — the telling part — construct the global infrastructure for AI-led bioengineering, including the translational and clinical development machinery its candidates need to reach patients.
That shift matters because the bottleneck in AI drug discovery is no longer generating candidates. It is proving them. No AI-designed medicine has yet reached the market, and the clinic is where every model-first claim meets its hardest test: human biology, regulators, and years of trials. Isomorphic gave no date for its first human trial in the announcement, and the money will be judged on whether it produces one.
What to watch#
First, the trial itself: when Isomorphic’s first candidate enters human testing, and how much the company discloses about it, will say more than any funding round. Second, the valuation: October’s talks reportedly put the company at $40 billion or more, and the absence of a number in today’s announcement leaves the market guessing whether the price went up, down, or was simply kept private. Third, the partner pipeline: collaborations with Eli Lilly, Novartis and Johnson & Johnson, announced over the past two years, are where outside validation would show up first — in milestones reached, not press releases. And fourth, the field: with $7 billion raised in a single year, Isomorphic is now the biggest test of whether AI can design medicines at all. The models have the money. The clinic gets the verdict.
Sources: Isomorphic Labs (PR Newswire) (November 17, 2026, the announcement); Tech.eu (November 17, 2026); Unite.AI (November 17, 2026). See also our October coverage of the funding talks.
Frequently asked questions
What did Isomorphic Labs announce?
A $5 billion Series C funding round, announced November 17, 2026, co-led by Greenoaks and Sequoia Capital. The round was oversubscribed; Andreessen Horowitz joined as a new investor, Alphabet invested again, and all existing investors took part.
What is IsoDDE?
Isomorphic Labs’ proprietary drug-design engine. It unifies simulation AI models that work across therapeutic areas and drug types, exploring vast chemical spaces to design candidate molecules — paired with agents that reason over complex biological systems.
Has Isomorphic Labs put a drug into human trials yet?
Not yet. The company reports positive preclinical results in oncology and immunology programs, both internal and with partners, and says the new funding builds the infrastructure to advance its candidates into clinical trials. No timeline for the first human trial was given.